Sutro Biopharma (STRO) Q2 2026 earnings summary

Executive summary

• STRO-004 is the lead candidate in Phase 1 trials, showing early clinical activity, confirmed and unconfirmed partial responses, and a favorable safety profile in heavily pretreated advanced solid tumor patients as of July 2026.

• Rapid enrollment and dose optimization ongoing in the STRO-004 STR/VE-01 study, with no maximum tolerated dose defined yet.

• Restructuring in 2025 and 2026 prioritized three preclinical ADC programs, reduced workforce by two-thirds, and transitioned manufacturing to external partners.

• Collaborations with Astellas, Vaxcyte, and Ipsen remain key, though Ipsen terminated its STRO-003 program in 2025.

• Pipeline progress includes STRO-006 expected to enter the clinic in Q3 2026 and a second dual-payload iADC program with Astellas anticipated to start in the second half of 2026.

Financial highlights

• Revenue for Q2 2026 was $9.8M, with year-over-year comparisons differing due to the end of Ipsen revenue and growth from Astellas collaboration.

• Net loss for Q2 2026 was $38.5M, or $2.33 per share, compared to $11.5M, or $1.35 per share, in Q2 2025.

• Operating expenses for the first half of 2026 were $83.9M, a 45% decrease year-over-year, reflecting restructuring and cost reductions.

• Cash, cash equivalents, and marketable securities totaled $164.3M as of June 30, 2026, expected to fund operations into at least Q2 2028.

• February 2026 equity offering raised $110M gross proceeds.

Outlook and guidance

• Cash runway expected to fund operations for at least 12 months from the filing date, with some projections extending into Q2 2028.

• Next STRO-004 clinical update and expansion cohorts planned for the first half of 2027; STRO-006 Phase 1 trial initiation expected in Q3 2026; STRO-227 IND submission planned for 2026.

• Astellas collaboration expected to bring a second program into the clinic by end of 2026.

• Additional capital will be needed to support ongoing R&D and operations beyond the current runway.